Modified anti-CD52 antibody

Details Modified anti-CD52 antibody Modified anti-CD52 antibody

2011-03-22

2011-03-22

Bristol, Lynn (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C530S387100

Reexamination Certificate

active

07910104

ABSTRACT:
The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.

REFERENCES:
patent: 6569430 (2003-05-01), Waldmann et al.
patent: 6982321 (2006-01-01), Winter
patent: 2003/0153043 (2003-08-01), Carr et al.
patent: 2003/0157641 (2003-08-01), Reff et al.
patent: 2004/0180386 (2004-09-01), Carr et al.
patent: 0699755 (1996-03-01), None
patent: WO 92/01059 (1992-01-01), None
patent: WO 93/10817 (1993-06-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 98/59244 (1998-12-01), None
patent: WO 99/53038 (1999-10-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 02/30460 (2002-04-01), None
patent: WO 03/042247 (2003-05-01), None
Dufner (Trends Biotechnol. 24(11):523-29 (2006)).
MacCallum et al. (J. Mol. Biol. (1996) 262:732-745).
De Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. (2002) J. Mol. Biol. 320, 415-428.
Holm et al (2007) Mol. Immunol. 44: 1075-1084.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Asano et al., “Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment,”J. Biochem., 132:903-909, 2002.
Cheung et al., “A recombinant human Fab expressed inEscherichia colineutralizes rabies virus,”J Virol., 66:6714-6720, 1992.
Cobbold et al., “A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants,” .J. Immunol Methods, 127:19-24, 1990.
Dyer, “Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype,”Blood, 73:1431-1439, 1989.
Dyer, “The Role of CAMPATH-I Antibodies in the Treatment of Lymphoid Malignancies,”Seminars in Oncology, 26:52-57, 1999.
Friend et al., “Reversal of allograft rejection using the monoclonal antibody, campath-1G,”Transplant. Proc, 23:2253-2254, 1991.
Hale et al., “Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection,”Blood, 92:4581-4590, 1998.
Hale et al., “Removal of t cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement,”Blood, 62:873-882, 1983.
Riechmann et al., “Reshaping human antibodies for therapy,”Nature, 332:323-327, 1988.
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,”Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
Schnitzer et al., “Subcutaneous administration of campath-lh: clinical and biological outcomes,”J Rheumatol, 24:1031-1036, 1997.
Takeda et al., “Two-phase approach for the expression of high-affinity human anti-human immunodeficiency virus immunoglobulin Fab domains inEscherichia coli,” Hybridoma, 14:9-18, 1995.
Weinblatt et al., “CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis,”Arthritis Rheum, 38:1589-1594, 1995.
Office Communication issued in corresponding Japanese application No. 2006-537487 mailed on Jul. 26, 2010 (English translation).

Affiliated with

Also associated with

Rating

Modified anti-CD52 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modified anti-CD52 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified anti-CD52 antibody will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2773072